AR129864A1 - Péptidos y métodos para uso en tratar el dolor - Google Patents

Péptidos y métodos para uso en tratar el dolor

Info

Publication number
AR129864A1
AR129864A1 ARP220103509A ARP220103509A AR129864A1 AR 129864 A1 AR129864 A1 AR 129864A1 AR P220103509 A ARP220103509 A AR P220103509A AR P220103509 A ARP220103509 A AR P220103509A AR 129864 A1 AR129864 A1 AR 129864A1
Authority
AR
Argentina
Prior art keywords
peptide
peptides
expression
nucleic acid
acid sequence
Prior art date
Application number
ARP220103509A
Other languages
English (en)
Spanish (es)
Inventor
Stphane Gaillard
Francis Castets
Abdelaziz Moqrich
Original Assignee
Tafalgie Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tafalgie Therapeutics filed Critical Tafalgie Therapeutics
Publication of AR129864A1 publication Critical patent/AR129864A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP220103509A 2021-12-17 2022-12-19 Péptidos y métodos para uso en tratar el dolor AR129864A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21306835 2021-12-17

Publications (1)

Publication Number Publication Date
AR129864A1 true AR129864A1 (es) 2024-10-09

Family

ID=79317102

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103509A AR129864A1 (es) 2021-12-17 2022-12-19 Péptidos y métodos para uso en tratar el dolor

Country Status (12)

Country Link
US (1) US20250051395A1 (cg-RX-API-DMAC7.html)
EP (1) EP4447991A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024547029A (cg-RX-API-DMAC7.html)
KR (1) KR20240126864A (cg-RX-API-DMAC7.html)
CN (1) CN118401249A (cg-RX-API-DMAC7.html)
AR (1) AR129864A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022413983A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239578A1 (cg-RX-API-DMAC7.html)
IL (1) IL313183A (cg-RX-API-DMAC7.html)
MX (1) MX2024007301A (cg-RX-API-DMAC7.html)
TW (1) TW202344689A (cg-RX-API-DMAC7.html)
WO (1) WO2023111348A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Also Published As

Publication number Publication date
TW202344689A (zh) 2023-11-16
JP2024547029A (ja) 2024-12-26
AU2022413983A1 (en) 2024-06-13
KR20240126864A (ko) 2024-08-21
CA3239578A1 (en) 2023-06-22
MX2024007301A (es) 2024-06-26
CN118401249A (zh) 2024-07-26
US20250051395A1 (en) 2025-02-13
EP4447991A1 (en) 2024-10-23
WO2023111348A1 (en) 2023-06-22
IL313183A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
CL2021000549A1 (es) Péptido asociado a tumor (tumap); ácido nucleico; vector de expresión; célula hospedadora recombinante que comprende el péptido; método para producir el péptido; composición farmaceutica; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico (divisional de la solicitud no. 201900460)
CL2022000458A1 (es) Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604)
JP7733226B2 (ja) 抗老化活性を有するペプチド及びその用途
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
UY27378A1 (es) Composición farmacéutica
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
BR112021025948A2 (pt) Polipeptídeos antimicrobianos derivados de bacteriófagos e seu uso contra bactérias gram-negativas e ácido-resistentes
MX2020013772A (es) Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber.
MX2023003817A (es) Métodos para desencadenar mecanismos de eliminación de seguridad mediante el uso de un agente bloqueador de cúmulo de diferenciación 47 (cd47)-proteína alfa reguladora de la señal (sirpa).
ES2174921T3 (es) Inhibidores de la proteasa del vih.
JP2024536828A (ja) 抗老化活性を有するペプチド及びその用途
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
WO2024256710A3 (en) Engineered lysin polypeptide constructs active against gram-negative bacteria
US20170232064A1 (en) Formulations for histatin therapeutics
MX2020003810A (es) Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.
MX2024007301A (es) Peptidos y metodos para usar en el tratamiento del dolor.
PE20212072A1 (es) Composiciones utiles en el tratamiento de la enfermedad de krabbe
GT200000224A (es) Composicion para el tratamiento de tejidos dañados.
JOP20240271A1 (ar) ببتيدات إظهار أنشطة منع فقدان العضلات وتعزيز الكتلة العضلية واستخداماتها
CL2024002500A1 (es) Inhibidores de proteínas de unión a emopamilo y usos de estos
KR102774179B1 (ko) 항노화 활성을 갖는 펩타이드 및 이의 용도
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
JP2014514342A (ja) タンパク質trf2の調節物質である新規ペプチドおよびそれを含む組成物
BR112022007603A2 (pt) Métodos para o tratar hiperplasia epidermica congênita